<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681300</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200325</org_study_id>
    <nct_id>NCT04681300</nct_id>
  </id_info>
  <brief_title>Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing</brief_title>
  <acronym>PRURISEQ</acronym>
  <official_title>Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prurigo nodularis (PN) is a skin condition characterized by symmetrically distributed&#xD;
      widespread, pruritic nodules that occurs in patients with chronic pruritus. There are 2&#xD;
      subtypes of PN depending on the association with an atopic dermatitis (AD) : atopic PN&#xD;
      (Besnier) and non-atopic PN (Hyde). There are no approved therapies, and treatment options&#xD;
      currently used have limited efficacy and their long-term use carries the risk of potential&#xD;
      severe toxic effects.&#xD;
&#xD;
      The mechanisms triggering PN are still unknown. However, recent findings suggest a major role&#xD;
      for the Th2 inflammatory pathway.&#xD;
&#xD;
      Beyond advancing the basic understanding of PN pathophysiology, our study might also pave the&#xD;
      way for developing novel Th2-targeted therapeutic strategies for PN and AD. The primary&#xD;
      objective of this study is to characterize the transcriptional profile of the T lymphocytes&#xD;
      isolated from skin samples from patients with PN. This study will allow a gain a deeper&#xD;
      understanding of the pathophysiologic mechanism of PN, a better classification of its&#xD;
      subtypes, as well as their physiopathologic link with AD. Moreover, it will help shape new&#xD;
      effective and safe therapeutic approaches in these diseases which are important for optimal&#xD;
      therapeutic management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptional profile of the T lymphocytes</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory pathways</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular differences</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prurigo Nodularis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with plastic surgery interventions</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>a skin sample will be taken using a 4 mm punch biopsy in lesional skin</description>
    <arm_group_label>Patients with atopic Prurigo nodularis , non-atopic Prurigo nodularis or atopic dermatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plastic surgery remnants</intervention_name>
    <description>healthy skin from plastic surgery interventions</description>
    <arm_group_label>Patients with plastic surgery interventions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with confirmed diagnosis of atopic dermatitis (n=5), atopic prurigo&#xD;
        nodularis (of Besnier) (n=5) and non-atopic prurigo nodularis (of Hyde) (n=5) or from&#xD;
        surgical residues of normal skin (n=5).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 18 years of age&#xD;
&#xD;
          -  Signature of the written contentment&#xD;
&#xD;
          -  Clinical diagnostic of PN defined by the following: a minimum of 20 PN lesions, in&#xD;
             total on both legs, and/or both arms; an average worst itch score of ≥7. Atopic PN&#xD;
             will be defined as PN associating clinical sings or history of AD according to Hanifin&#xD;
             et Rajka criteria. Non-Atopic PN will be defined as PN non-associated with clinical&#xD;
             sings or history of AD according to Hanifin et Rajka criteria.&#xD;
&#xD;
          -  or confirmed diagnosis of AD according to Hanifin et Rajka criteria without associated&#xD;
             PN.&#xD;
&#xD;
          -  Washout period for topical treatments (&gt; 1 week) ans systemic treatments (&gt; 1 month).&#xD;
&#xD;
          -  Indication and absence of contraindication to performing a skin biopsy as part of the&#xD;
             treatment&#xD;
&#xD;
        Inclusion criteria for healthy controls:&#xD;
&#xD;
          -  more than 18 years of age&#xD;
&#xD;
          -  Signature of the written contentment&#xD;
&#xD;
          -  Hospitalised in the plastic surgery department of Saint-Louis Hospital.&#xD;
&#xD;
          -  No associated inflammatory or tumoral skin condition&#xD;
&#xD;
          -  No contraindication for biopsy&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Presence of inflammatory or tumoral skin morbidities other than PN and atopic&#xD;
             dermatitis&#xD;
&#xD;
          -  Treatment induced pruritus&#xD;
&#xD;
          -  Pruritus secondary to other medical conditions such as bullous dermatosis, renal&#xD;
             insufficiency, infectious diseases, …)&#xD;
&#xD;
          -  AD under biologic therapy&#xD;
&#xD;
          -  Patient under guardianship or conservatorship&#xD;
&#xD;
          -  No health insurance coverage&#xD;
&#xD;
          -  Patient under State Medical Assistance (AME)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Persons deprived of their liberty by a judicial or administrative decision&#xD;
&#xD;
          -  People undergoing psychiatric care making their consent impossible&#xD;
&#xD;
          -  Adults who are the subject of a legal protection measure or unable to express their&#xD;
             consent&#xD;
&#xD;
          -  Patients unable to read and write&#xD;
&#xD;
        Exclusion criteria for healthy controls:&#xD;
&#xD;
          -  Inflammatory or tumoral medical condition&#xD;
&#xD;
          -  Biological therapy for any other medical condition&#xD;
&#xD;
          -  Associated inflammatory or tumoral skin condition&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Persons deprived of their liberty by a judicial or administrative decision&#xD;
&#xD;
          -  People undergoing psychiatric care making their consent impossible&#xD;
&#xD;
          -  Adults who are the subject of a legal protection measure or unable to express their&#xD;
             consent&#xD;
&#xD;
          -  Patients unable to read and write&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jean-David BOUAZIZ</last_name>
    <phone>01 42 49 43 19</phone>
    <email>jean-david.bouaziz@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu RESCHE-RIGON</last_name>
    <phone>+33142499742</phone>
    <email>matthieu.resche-rigon@univ-paris-diderot.fr</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

